Johns Hopkins moved up a spot to No. 10 in the annual U.S. News & World Report Best Global University Rankings released today, a year after moving up to No. 11 from No. 12 in the 2020 rankings.

Johns Hopkins also ranks among the top 10 universities in the world in 15 subject areas and among the top 20 in 19 subject areas. Ten new subject area rankings were added to the list this year, bringing the total to 38.


NEA’s Scott Sandell Photographer: David Paul Morris/Bloomberg

New Enterprise Associates Inc., one of the world’s largest venture capital firms, is in talks to sell a minority stake in itself, according to people with knowledge of the matter.

The Silicon Valley firm has held discussions with several potential investors, said the people, who requested anonymity because the talks are private. No deal has been reached, and it’s possible one won’t materialize. Representatives for NEA didn’t immediately respond to requests for comment.

Image: NEA’s Scott Sandell Photographer: David Paul Morris/Bloomberg

Person Holding Injection Free Stock Photo

In a long-awaited meeting on America’s crash program to deliver vaccines against the Covid-19 coronavirus, leaders of the program reviewed the measures they have taken to assure the effectiveness and safety of the vaccines. The U.S. Food and Drug Administration convened a panel of independent vaccine experts to ask questions during the Thursday online session. The meeting was designed to reassure the public on the integrity and transparency of the FDA’s vaccine oversight, as the agency has wrestled with political pressure and pockets of public vaccine hesitancy.


Brexit Logo


The UK formally left the EU on 31st January  2020 and the transition period, as set out in the withdrawal agreement, will come to an end on 31st December  2020. During this transition period the UK has continued to remain under EU pharmaceutical law.

From 1st January 2021 the UK will be able to adopt an independent regulatory framework with the Medicines and Healthcare products Regulatory Agency (MHRA) positioned as the stand-alone regulator for medicines and medical devices.

Negotiations between the EU and UK are still ongoing to define the future relationship and with only a matter of months left before the end of the transition period there has been no formal agreement. For the pharmaceutical industry this presents numerous challenges as companies prepare to continue supply of medicines that comply with new legislation. The preferred outcome for many within the industry will be to implement a mutual recognition agreement for areas such as GMP certification, batch testing, etc. between the UK and EU.  It is unclear at this stage if an encompassing mutual recognition agreement is achievable so all involved parties should be preparing for a ‘no deal’ scenario and review existing guidance to understand risk exposure and mitigating actions.

ASME logo

Last week, the Department of Defense (DOD) announced a seven-year award of $87 million for a new Manufacturing USA institute: BioMADE. The BioIndustrial Manufacturing and Design Ecosystem (BioMADE) institute joins a network of 8 other DOD institutes, making for a total of 16 institutes supported across the federal government in the Manufacturing USA program. ASME has been a long-time supporter and advocate of the Manufacturing USA program.



Different geographies and jurisdictions play different roles in the global economy. Some specialize in what economists call “seedbed” functions—generating new products and firms, often through cutting-edge innovation. Others specialize in corporate functions by offering attractive environments for company headquarters or other management activities. Still others specialize in more routine production functions for goods or services, handling aspects of the work that involve less innovation and have lower skill requirements. Finally, some regions specialize in resource production tied to geographical endowments, such as minerals, arable land, or lumber.


TBJ Plus Blueprint for economic recovery beyond Raleigh Durham Film crews return to NC Wait times for voting in Wake County Triangle Business Journal

BLUEPRINT FOR ECONOMIC RECOVERY BEYOND THE TRIANGLE: Most experts agree Raleigh and Durham are well positioned for a strong recovery from the pandemic, but what about the areas well beyond the Triangle's core?

A new report released Wednesday from RTI International is meant to address that very question. The Innovation Corridor Blueprintincludes 12 areas of focus for leaders and stakeholders to tackle in a 100-mile radius around the Triangle. Topics range from digital infrastructure and affordable housing to biohealth technology and addressing systemic racism.

Image: An illustration of the Raleigh-Durham skylines. SEANPAVONEPHOTO

Biohealth Capital Region Cover Image

The Sixth Annual BioHealth Capital Region Forum brought together industry leaders from across the region who discussed the accomplishments and strengths of the region as its member companies continue to innovate new therapies and medicines in one of the strongest bio-hub regions in the United States.

The forum, which drew more than 1,100 registrants and included 59 world-class speakers and panelists, had a different look this year due to the ongoing COVID-19 pandemic. Instead of gathering together in the heart of the BioHealth Capital Region at AstraZeneca’s Gaithersburg facility, the forum was held virtually. The event offered multiple panels and keynotes that highlighted advancements made in the region across several areas, including cell and gene therapies, the use of artificial intelligence and the ongoing battle against COVID-19.



Recordings of Keynotes, Panels and the Fireside Chat Available Online

The 6th Annual BioHealth Capital Region (BHCR) Forum like many events in 2020, went virtual this year with over 1,200 online registrants and 59 speakers coming together. The Forum, which has been held at AstraZeneca (Formerly MedImmune) since 2014 in Gaithersburg, MD, brought together the BioHealth Industry with a full slate featuring leaders of industry, academia, and government. The common message throughout the entire agenda was how this region has continued to operate and innovate while working to help the world solve the COVID-19 Pandemic.

The 2020 Crab Trap Competition, typically held during the Forum, will take place at Noon on October 21st. The Crab Trap focuses on companies in therapeutics, diagnostics, medical devices, healthcare services, e-health, mobile health, electronic medical records, health informatics, and BioHealth cyber security. This years’ finalists include BrainScope, CARRTECH, Creative Bio-Peptides, innara HEALTH, and KaloCyte.

The entire 6th Annual BioHealth Capital Region is currently available by visiting

NOTE: If you haven’t already registered, please enter your information for immediate access. Click on the “Agenda” line to browser all the videos now available.

Justin Yang and Rich Bendis - Biotalk Cover Image

BARDA Director of the DRIVe Catalyst Office, Justin Yang, Joins BioTalk to share how BARDA collaborates with the BioHealth Industry, partners with Incubators, and helps fund innovation.

Listen now via Apple, Google, Spotify, and TuneIn

New BoardMembers

 New Members Continue BHI’s Commitment and Mission in the BioHealth Capital Region

ROCKVILLE, MARYLAND, October 20, 2020 The Board of Directors of BioHealth Innovation, Inc. (BHI) unanimously approved the appointments of three new board members, Sally Allain, Head of JLABS @ Washington, DC, Joseph F. Sanchez, PhD,  Director, Science Engagement, R&D North America, AstraZeneca, and Robert Silverman, Chief Business Officer, Alloy Therapeutics, Inc. BHI’s leadership also thanked outgoing Board of Director member Tracey Vetterick, formally of AstraZeneca for her contributions to the organization and support of many years.

AstraZeneca Logo

The U.S. government is providing roughly $486 million to AstraZeneca to accelerate the Big Pharma company’s experimental Covid-19 therapy.

The funds will be used to advance AstraZeneca’s antibody combination, AZD7442, into two phase-III clinical trials. The last-stage studies, expected to begin later this month or early next month, will involve more than 6,000 study participants at sites in and outside the United States. (Phase-III clinical trials are typically the last hurdle a pharmaceutical company must successfully clear before seeking approval for a new drug candidate.)


People of different ethenicities standing in a circle holding hands - Diversity.

What is MedTech Color?

MedTech Color is a non-profit organization focused on ensuring people of color enter, remain, and flourish in the medtech industry. There is immense untapped potential from people of color, and we’re committed to providing and promoting opportunities for them to make a meaningful contribution to the industry.


Stephen M. Hahn M.D.

JOHN WHYTE: You're watching "Coronavirus in Context." I'm Dr. John Whyte, chief medical officer at WebMD. Today I'm joined by Dr. Stephen Hahn. He's the commissioner of the US Food and Drug Administration. Dr. Hahn, thanks for joining me.

STEPHEN M HAHN: John, thank you. Really appreciate the opportunity, and it's great to be part of this webcast.

Image: Stephen M. Hahn M.D.


VC investment dollars hit a seven-quarter high in the U.S. in the third quarter of 2020: A total of $36.5 billion was invested in U.S. tech and healthcare companies, according to data from the MoneyTree Report by PwC/CB Insights. That’s up 30% from the second quarter. The total number of deals rose to 1,461 investments in companies, up 1% over the prior quarter.

It’s the second straight quarter of growth, indicating that a slowdown toward the end of March as the pandemic set in didn’t become the norm.

“Things are still going gangbusters,” said Brad Phillips, a director in PwC’s Emerging Company Services practice. “It’s been a relief for a lot of people that were in the market and just didn’t know what was going to happen.”

Image: Whitebox's Baltimore team inside its Curtis Bay HQ. (Courtesy photo)

Martha Choonmaker - Closeup Image

“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. This edition features 5 Questions Martha Schoonmaker, Executive Director, Pinkney Innovation Complex for Science and Technology at Montgomery College (PIC MC).

Martha Schoonmaker is the first Executive Director for the PIC MC Foundation, the entity that develops, manages, and markets the Germantown campus on behalf of Montgomery College for company locations. PIC MC is an integrated academic, business, and research campus and is the only community college with a hospital, Holy Cross Germantown Hospital, located as the anchor resident partner.



This event is free for biotech leaders is presented by BioHealth Innovation, VirginiaBio, Children’s National Health System, Deloitte, JLABS @ Washington D.C., Johns Hopkins University, Maryland Department of Commerce, Quality Biologics, George Mason University, University System of Maryland and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. Please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.


Palo Alto office buildings at 3450 Hillview Ave. and 3460 Hillview Ave. A big Southern California real estate and investment firm has gobbled up its latest in a string of Palo Alto office property purchases, a deal that extends a buying spree in the Silicon Valley tech hub that now tops $850 million.


PALO ALTO — A big Southern California real estate and investment firm has gobbled up its latest in a string of Palo Alto office property purchases, a deal that extends a buying spree in the Silicon Valley tech hub that now tops $850 million.

Alexandria Real Estate, acting through an affiliate, has bought two Palo Alto office buildings on Hillview Avenue near Arastradero Road, acquiring a site that’s in the famed Stanford Research Park.

The deal suggests investors still seek to collect commercial properties in choice and prestigious locations despite the economic uncertainties that the coronavirus has triggered.



Thank you for your interest in the 6th Annual BioHealth Capital Region Forum on Monday, October 19, 2020 that will highlight the accomplishments of today and chart our successes of tomorrow.

We are thrilled to welcome executive-level biohealth industry leaders from across the country and overseas. To make the best use of your time and enable you to network with our 1000+ registrants and learn from the 58+ industry speakers, please use the instructions below to join our virtual event platform,


JJLabs Logo

October 14, 2020 – Johnson & Johnson Innovation announced today at the virtual 2020 HLTH conference the awardees for the JLABS @ Washington, DC Children’s, Maternal Health, and Diversity in Innovation QuickFire Challenges, which respectively aimed to catalyze pediatric innovation, improve maternal health in the United States, and support diverse innovators. These challenges embody Johnson & Johnson Innovation’s commitment to catalyzing potential solutions to today’s greatest healthcare challenges.



At BioBuzz, we’re dedicated to bringing you interesting and important stories that emerge from the thriving life sciences ecosystem that is the BioHealth Capital Region (BHCR). 

The heart of the BHCR biohealth cluster is Maryland, with its vast network of government research agencies, the strong university system, and a deep network of established, emerging, and startup life science companies across a wide range of fields, including cell and gene therapy, advanced biomanufacturing, phage therapy, medical devices and more traditional biotech and pharma organizations. That’s not even to mention the remarkable efforts of myriad Maryland vaccine companies to develop the first approved, safe, and efficacious SARS-CoV-2 vaccine.


Emmes Logo

Emmes today announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2020 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post partnered with employee research and consulting firm Energage, and the process is based on a scientific survey of employees who rate their workplace culture.

The Post’s annual survey honored 200 organizations as Top Workplaces. Emmes was selected in the large company category, which included organizations with between 500 and 999 employees. More than 3,600 area companies were invited to have their employees take the survey.



If you’re located in New York City or the Silicon Valley, venture capital firms are abundant and well covered by the media — you can’t escape them. But entrepreneurs in the Baltimore-D.C. region don’t need to go so far to find a firm that could propel their startup to growth.

The local venture capital community is robust, with dozens of firms that invest in all sorts of industries, from healthcare to fintech to cybersecurity. And it’s part of the reason that in 2016, approximately $1.09 billion was invested in local high-tech startups by VC firms, placing the region in the top 10 funded clusters in the U.S.


AstraZeneca Logo

To meet the Trump Administration’s Operation Warp Speed goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD) today announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing  of the company’s COVID-19 investigational product AZD7442, a cocktail of two monoclonal antibodies, that may help treat or prevent infection with SARS-CoV-2, the coronavirus that causes COVID-19.


Brett Malone, Ph.D., President & CEO Virginia Tech Corporate Research Center

Not every research project succeeds. And not every company survives. However, the ones that align with the culture of winning and sign up and adopt the community charter are opting in for a much higher chance of disrupting their industry and changing the rules of the game.

So, you are probably thinking it’s not important, right?

But it is... At the Virginia Tech Corporate Research Center, we have the unique ability to witness effective project teams daily. With over 200 companies creating breakthroughs from nanomaterials to self-driving vehicles, we have a ready-made ‘team laboratory’ to understand what works and how to scale.

Image: Brett Malone, Ph.D., President & CEO Virginia Tech Corporate Research Center

BHCR Forum Save the Date 08242020 pdf 1 page

Join fellow biotech leaders and is presented by the Association of University Research Parks, AstraZeneca, BioHealth Innovation, Children’s National Health System, Emergent BioSolutions, George Mason University, J.P. Morgan, Johns Hopkins University, Maryland Department of Commerce, Virginia Bio, and Wilson Sonsini Goodrich & Rosati, P.C.

Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

We are excited to bring you an exceptional line up of more than 55 BioHealth Capital Region industry leaders to this virtual event!



Montgomery County Economic Development Corporation (MCEDC)  President and CEO  Benjamin Wu Chats with Rich Bendis on BioTalk.

Listen now Apple, Google, Spotify, and YouTube Audio

As the President and Chief Executive Officer of MCEDC, Ben Wu leads the public-private economic development of Maryland’s largest jurisdiction which comprises 25% of the state’s economy with a GDP greater than 13 states. A Montgomery County native, Ben is an accomplished executive with over three decades of professional experience leading operations at the highest levels of our nation and state.

Maryland Gov. Larry Hogan (2d from left) chats with Gale Smith, PhD, Novavax Discovery and Preclinical Research and Chief Scientist, during a tour of the company’s Gaithersburg, MD, facilities. (Office of Governor Larry Hogan)

When Maryland Gov. Larry Hogan visited Novavax recently, President and CEO Stanley C. Erck shared some welcome news for the governor publicly: Novavax had more than doubled its workforce so far this year, adding 116 people to the 100 that it employed at the start of 2020.

“The plan is to double that again, to add another 200 in the coming six months just in the U.S.,” Erck said, part of an expansion plan by Novavax to grow its workforce to 1,000 people worldwide. Novavax recently expanded into a third building at its Gaithersburg, MD, headquarters, and is also in talks for an additional 200,000 square feet of lab space locally.

Image: Maryland Gov. Larry Hogan (2d from left) chats with Gale Smith, PhD, Novavax Discovery and Preclinical Research and Chief Scientist, during a tour of the company’s Gaithersburg, MD, facilities. (Office of Governor Larry Hogan)

NexImmune Logo

GAITHERSBURG, MD -- October 6, 2020 – NexImmune, a clinical-stage biotechnology company developing a portfolio of unique non-genetically-engineered T cell immunotherapies, announced today that it has dosed the first patient in its Phase 1/2 clinical trial for NEXI-002. NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets. It is the second clinical product NexImmune has generated with its AIM nanoparticle technology.

“While the primary objective in this trial with NEXI-002 is to demonstrate safety and tolerability, we also hope to see initial signs of immunological and clinical activity,” said Han Myint, MD, Chief Medical Officer at NexImmune. “The AIM technology gives us the unique ability to direct populations of natural T cells against a powerful combination of cell surface and endogenous anti-tumor targets specific to multiple myeloma. We believe this approach has potential to address primary tumor escape mechanisms, and provide deep and durable clinical responses.”


Glyco Mimetics Logo

ROCKVILLE, Md.–(BUSINESS WIRE)–Oct. 5, 2020– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle cell disease in patients 18 years old and younger. This designation recognizes the significant needs in pediatric patients.

“The FDA’s designation recognizes the morbidity and mortality burdens of sickle cell disease as well as its significant impact during childhood with life-long implications. With this designation, the agency acknowledges the urgent need for improved treatment of children living with sickle cell disease,” stated Helen Thackray, Chief Medical Officer of GlycoMimetics.